Treating androgen decline in aging male (adam)-associated conditions with sarms

A method of preventing a male subject suffering from an Androgen Decline in Aging Male (ADAM)-associated condition, wherein said ADAM-associated condition is selected from the group consisting of fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer, said method comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula I:

• wherein
• G is O or S;
• X is O;
• T is OH, OR, —NHCOCH3, or NHCOR;
• Z is NO2, CN, COOH, COR, NHCOR or CONHR;
• Y is CF3, F, I, Br, Cl, CN, C(R)3 or Sn(R)3;
• Q is alkyl, F, Cl, Br, I, CF3, CN, C(R)3, Sn(R)3, N(R)2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R, SR, NCS, SCN, NCO, OCN;
• R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
• and
• R1 is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3;
• or its optical isomer or pharmaceutically acceptable salt, or any combination thereof.